表皮水疱症の世界市場レポート 2025年

表皮水疱症の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.3％で45億9,000万米ドルに成長すると予想されます。予測期間中の成長は、再生医療や幹細胞治療の採用増加、認知度や診断率の向上、遺伝子治療や細胞治療の承認拡大、創傷治療の拡大、診断症例の増加などに起因しています。この期間の主な動向としては、新規治療、幹細胞治療、遺伝子編集技術、標的治療、戦略的提携、遺伝子研究の進展などが挙げられます。

表皮水疱症市場の成長は、研究開発活動の活発化によって牽引されると予想されます。これらの活動には、新製品、プロセス、技術を革新、改善、創造するための体系的な取り組みが含まれます。研究開発の増加は、複雑な疾患に取り組むための革新的な治療法、先進的な治療法、精密医療に対する需要の高まりに起因しています。その結果、このような努力は、診断、管理、そして表皮水疱症を持つ人々の全体的な生活の質を向上させる、新しい治療法、先進的な創傷ケアソリューション、潜在的な遺伝子・細胞ベースの治療法の発見につながっています。例えば、2024年4月、英国の国家統計局は、政府の研究開発費（EU拠出金を除く）が2021年の173億米ドルから2022年には10.5％増の約192億米ドルになると報告しました。その結果、研究開発活動の高まりが市場の成長に寄与しています。

表皮水疱症市場の企業は、長期的な有効性と患者の転帰の改善を目指す再利用可能な遺伝子治療などのイノベーションにますます注力しています。従来の1回限りの遺伝子治療とは異なり、再利用可能な遺伝子治療は複数回投与することで治療効果を維持・向上させることができます。例えば、2023年5月、米国を拠点とするバイオテクノロジー企業であるKrystal Biotech Inc.は、生後6ヵ月以上のジストロフィー表皮水疱症（DEB）を治療するための再利用可能な遺伝子治療薬であるVYJUVEKをFDAが承認したと発表しました。VYJUVEKはCOL7A1遺伝子の機能的コピーを投与し、DEBの根本的な遺伝的欠陥に対処します。この局所療法は、従来の治療法よりも低侵襲で簡便な代替療法であり、患者のケアと利用しやすさを向上させることができます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の表皮水疱症市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の表皮水疱症市場：成長率分析
• 世界の表皮水疱症市場の実績：規模と成長、2019～2024年
• 世界の表皮水疱症市場の予測：規模と成長、2024～2029年、2034年
• 世界の表皮水疱症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の表皮水疱症市場：製品タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗生物質
• 鎮痛剤
• その他
• 世界の表皮水疱症市場：投与方法別、実績と予測、2019～2024年、2024～2029年、2034年
• 注射
• 経口
• その他
• 世界の表皮水疱症市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• ホームケア
• 専門クリニック
• その他
• 世界の表皮水疱症市場：抗生物質のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 局所抗生物質
• 経口抗生物質
• 注射用抗生物質
• 世界の表皮水疱症市場：鎮痛剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• NSAID
• オピオイド
• 局所鎮痛剤
• 世界の表皮水疱症市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 創傷被覆材
• 免疫療法
• 遺伝子治療

第7章 地域別・国別分析

• 世界の表皮水疱症市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の表皮水疱症市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 表皮水疱症市場：競合情勢
• 表皮水疱症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • CHIESI Farmaceutici S.p.A Overview, Products and Services, Strategy and Financial Analysis
  • Shionogi Inc. Overview, Products and Services, Strategy and Financial Analysis
  • LEO Pharma A/S Overview, Products and Services, Strategy and Financial Analysis
  • BridgeBio Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amicus Therapeutics Inc.
• Amryt Pharma plc
• Krystal Biotech Inc.
• Castle Creek Biosciences Inc.
• C4U Corporation
• RHEACELL GmbH & Co. KG
• Aegle Therapeutics Corp.
• BioMendics LLC
• InMed Pharmaceuticals Inc.
• BPGbio Inc.
• ProQR Therapeutics N.V.
• Holostem Terapie Avanzate Srl
• TWi Biotechnology Inc.
• Abeona Therapeutics Inc.
• RegeneRx Biopharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 表皮水疱症市場2029：新たな機会を提供する国
• 表皮水疱症市場2029：新たな機会を提供するセグメント
• 表皮水疱症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Epidermolysis bullosa (EB) refers to a group of rare genetic disorders that result in extremely fragile skin, causing blistering and wounds from even minor friction or trauma. These conditions are important for studying genetic skin diseases, advancing wound care treatments, and developing innovative gene and cell therapies to improve patient outcomes.

The main product types for epidermolysis bullosa include antibiotics, analgesics, and other treatments. Antibiotics are medications used to treat bacterial infections by either killing bacteria or inhibiting their growth. These medications are administered through various methods, including injectables, oral treatments, and others. They are used by various end users, such as hospitals, home care providers, specialty clinics, and more.

The epidermolysis bullosa market research report is one of a series of new reports from The Business Research Company that provides epidermolysis bullosa market statistics, including the epidermolysis bullosa industry global market size, regional shares, competitors with the epidermolysis bullosa market share, detailed epidermolysis bullosa market segments, market trends, and opportunities, and any further data you may need to thrive in the epidermolysis bullosa industry. This epidermolysis bullosa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The epidermolysis bullosa market size has grown strongly in recent years. It will grow from $3.22 billion in 2024 to $3.46 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to the rise in clinical trials, the increasing prevalence of epidermolysis bullosa, greater awareness, and a surge in research funding. Additionally, there has been an increasing focus on gene therapy and the treatment of rare diseases.

The epidermolysis bullosa market size is expected to see strong growth in the next few years. It will grow to $4.59 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth during the forecast period can be attributed to the rising adoption of regenerative medicine and stem cell therapy, increased awareness and diagnosis rates, growing approvals of gene and cell therapies, expanding wound care, and a rise in diagnosed cases. Key trends during this period include novel therapies, stem cell treatments, gene editing technology, targeted therapies, strategic collaborations, and advancements in genetic research.

The growth of the epidermolysis bullosa market is expected to be driven by the increasing activities in research and development. These activities involve systematic efforts to innovate, improve, or create new products, processes, or technologies. The rise in research and development can be attributed to the growing demand for innovative treatments, advanced therapies, and precision medicine to tackle complex diseases. As a result, these efforts are leading to the discovery of novel therapies, advanced wound care solutions, and potential gene and cell-based treatments that improve diagnosis, management, and the overall quality of life for those with epidermolysis bullosa. For example, in April 2024, the Office for National Statistics in the UK reported that the government's research and development spending (excluding EU contributions) rose by 10.5% to approximately $19.2 billion in 2022, up from $17.3 billion in 2021. Consequently, the rising emphasis on research and development is contributing to the market's growth.

Companies in the epidermolysis bullosa market are increasingly focusing on innovations such as redosable gene therapy, which aims to improve long-term efficacy and patient outcomes. Unlike traditional one-time gene therapies, redosable gene therapy can be administered multiple times to maintain or enhance its therapeutic effects. For instance, in May 2023, Krystal Biotech Inc., a U.S.-based biotechnology firm, announced that the FDA had approved VYJUVEK, a redosable gene therapy for treating dystrophic epidermolysis bullosa (DEB) in patients aged six months and older. VYJUVEK delivers a functional copy of the COL7A1 gene to address the underlying genetic defect of DEB. This topical therapy provides a less invasive and more convenient alternative to traditional treatments, improving patient care and accessibility.

In August 2023, Paradigm Therapeutics Inc., a U.S.-based biopharmaceutical company, acquired the global rights to SD-101 from Amicus Therapeutics for an undisclosed amount. Through this acquisition, Paradigm Therapeutics aims to further the development of this breakthrough therapy, which is designed to treat all subtypes of epidermolysis bullosa. This move is intended to accelerate the potential of SD-101 as a groundbreaking treatment solution for patients with the condition. Amicus Therapeutics, known for its focus on gene therapies, wound care, and innovative drugs for epidermolysis bullosa, was instrumental in developing this therapeutic approach.

Major players in the epidermolysis bullosa market are Pfizer Inc., CHIESI Farmaceutici S.p.A, Shionogi Inc., LEO Pharma A/S, BridgeBio Pharma Inc., Amicus Therapeutics Inc., Amryt Pharma plc, Krystal Biotech Inc., Castle Creek Biosciences Inc., C4U Corporation, RHEACELL GmbH & Co. KG, Aegle Therapeutics Corp., BioMendics LLC, InMed Pharmaceuticals Inc., BPGbio Inc., ProQR Therapeutics N.V., Holostem Terapie Avanzate Srl, TWi Biotechnology Inc., Abeona Therapeutics Inc., and RegeneRx Biopharmaceuticals Inc.

North America was the largest region in the epidermolysis bullosa market in 2024. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the epidermolysis bullosa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The epidermolysis bullosa market consists of sales of wound care dressings, topical creams, gene therapy products, skin grafts, and pain management medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Epidermolysis Bullosa Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on epidermolysis bullosa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for epidermolysis bullosa ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The epidermolysis bullosa market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Antibiotic; Analgesics; Other Product Types
• 2) By Mode Of Administration: Injectables; Oral; Other Modes of Administration
• 3) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Antibiotic: Topical Antibiotics; Oral Antibiotics; Injectable Antibiotics
• 2) By Analgesics: NSAIDs; Opioids; Topical Pain Relievers
• 3) By Other Product Types: Wound Dressings; Immunotherapies; Gene Therapies
• Companies Mentioned: Pfizer Inc.; CHIESI Farmaceutici S.p.A; Shionogi Inc.; LEO Pharma A/S; BridgeBio Pharma Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Epidermolysis Bullosa Market Characteristics

3. Epidermolysis Bullosa Market Trends And Strategies

4. Epidermolysis Bullosa Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Epidermolysis Bullosa Growth Analysis And Strategic Analysis Framework

• 5.1. Global Epidermolysis Bullosa PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Epidermolysis Bullosa Market Growth Rate Analysis
• 5.4. Global Epidermolysis Bullosa Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Epidermolysis Bullosa Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Epidermolysis Bullosa Total Addressable Market (TAM)

6. Epidermolysis Bullosa Market Segmentation

• 6.1. Global Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotic
• Analgesics
• Other Product Types
• 6.2. Global Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectables
• Oral
• Other Mode Of Administrations
• 6.3. Global Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.4. Global Epidermolysis Bullosa Market, Sub-Segmentation Of Antibiotic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Antibiotics
• Oral Antibiotics
• Injectable Antibiotics
• 6.5. Global Epidermolysis Bullosa Market, Sub-Segmentation Of Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• NSAIDs
• Opioids
• Topical Pain Relievers
• 6.6. Global Epidermolysis Bullosa Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wound Dressings
• Immunotherapies
• Gene Therapies

7. Epidermolysis Bullosa Market Regional And Country Analysis

• 7.1. Global Epidermolysis Bullosa Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Epidermolysis Bullosa Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Epidermolysis Bullosa Market

• 8.1. Asia-Pacific Epidermolysis Bullosa Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Epidermolysis Bullosa Market

• 9.1. China Epidermolysis Bullosa Market Overview
• 9.2. China Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Epidermolysis Bullosa Market

• 10.1. India Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Epidermolysis Bullosa Market

• 11.1. Japan Epidermolysis Bullosa Market Overview
• 11.2. Japan Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Epidermolysis Bullosa Market

• 12.1. Australia Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Epidermolysis Bullosa Market

• 13.1. Indonesia Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Epidermolysis Bullosa Market

• 14.1. South Korea Epidermolysis Bullosa Market Overview
• 14.2. South Korea Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Epidermolysis Bullosa Market

• 15.1. Western Europe Epidermolysis Bullosa Market Overview
• 15.2. Western Europe Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Epidermolysis Bullosa Market

• 16.1. UK Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Epidermolysis Bullosa Market

• 17.1. Germany Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Epidermolysis Bullosa Market

• 18.1. France Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Epidermolysis Bullosa Market

• 19.1. Italy Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Epidermolysis Bullosa Market

• 20.1. Spain Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Epidermolysis Bullosa Market

• 21.1. Eastern Europe Epidermolysis Bullosa Market Overview
• 21.2. Eastern Europe Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Epidermolysis Bullosa Market

• 22.1. Russia Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Epidermolysis Bullosa Market

• 23.1. North America Epidermolysis Bullosa Market Overview
• 23.2. North America Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Epidermolysis Bullosa Market

• 24.1. USA Epidermolysis Bullosa Market Overview
• 24.2. USA Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Epidermolysis Bullosa Market

• 25.1. Canada Epidermolysis Bullosa Market Overview
• 25.2. Canada Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Epidermolysis Bullosa Market

• 26.1. South America Epidermolysis Bullosa Market Overview
• 26.2. South America Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Epidermolysis Bullosa Market

• 27.1. Brazil Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Epidermolysis Bullosa Market

• 28.1. Middle East Epidermolysis Bullosa Market Overview
• 28.2. Middle East Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Epidermolysis Bullosa Market

• 29.1. Africa Epidermolysis Bullosa Market Overview
• 29.2. Africa Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Epidermolysis Bullosa Market Competitive Landscape And Company Profiles

• 30.1. Epidermolysis Bullosa Market Competitive Landscape
• 30.2. Epidermolysis Bullosa Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. CHIESI Farmaceutici S.p.A Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Shionogi Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. LEO Pharma A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. BridgeBio Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Epidermolysis Bullosa Market Other Major And Innovative Companies

• 31.1. Amicus Therapeutics Inc.
• 31.2. Amryt Pharma plc
• 31.3. Krystal Biotech Inc.
• 31.4. Castle Creek Biosciences Inc.
• 31.5. C4U Corporation
• 31.6. RHEACELL GmbH & Co. KG
• 31.7. Aegle Therapeutics Corp.
• 31.8. BioMendics LLC
• 31.9. InMed Pharmaceuticals Inc.
• 31.10. BPGbio Inc.
• 31.11. ProQR Therapeutics N.V.
• 31.12. Holostem Terapie Avanzate Srl
• 31.13. TWi Biotechnology Inc.
• 31.14. Abeona Therapeutics Inc.
• 31.15. RegeneRx Biopharmaceuticals Inc.

32. Global Epidermolysis Bullosa Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Epidermolysis Bullosa Market

34. Recent Developments In The Epidermolysis Bullosa Market

35. Epidermolysis Bullosa Market High Potential Countries, Segments and Strategies

• 35.1 Epidermolysis Bullosa Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Epidermolysis Bullosa Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Epidermolysis Bullosa Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer